Alaunos Therapeutics, Inc. (TCRT)
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $5.0K
- Net income
- -$4.2M
- Total assets
- $3.0M
- Market cap
- $5.6M
- Operating margin
- -84500.0%
- Net margin
- -83520.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $5.0K
- Operating expenses
- $4.2M
- Operating income
- -$4.2M
- Income tax
- $0
- Net income
- -$4.2M
- EPS (basic)
- $-2.20
- EPS (diluted)
- $-2.20
Balance sheet
- Total assets
- $3.0M
- Current assets
- $2.0M
- Total liabilities
- $813.0K
- Current liabilities
- $813.0K
- Shareholders’ equity
- $2.2M
Cash flow
- Operating cash flow
- -$2.9M
- Investing cash flow
- -$98.0K
- Financing cash flow
- $3.3M
- Net cash flow
- $294.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $5.6M
- EPS (diluted)
- $-2.2
- Shares outstanding
- 2.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 24, 2005
Alaunos Therapeutics, Inc. (TCRT) Stock Price
- Reported a net loss of $4.2M in FY2025.
- Revenue declined 100% from FY2022 to FY2025.
- Trading 62% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Alaunos Therapeutics, Inc..
Write a review
News about Alaunos Therapeutics, Inc.
News & sentiment via Polygon.io
Alaunos Therapeutics, Inc.: frequently asked questions
Is Alaunos Therapeutics, Inc. an American company?
Alaunos Therapeutics, Inc. is a US-based company headquartered in Fort Lauderdale, Florida, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Alaunos Therapeutics, Inc. headquartered?
Alaunos Therapeutics, Inc. is headquartered in Fort Lauderdale, Florida, United States.
Is Alaunos Therapeutics, Inc. publicly traded?
Yes — Alaunos Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol TCRT on the NASDAQ.
What does Alaunos Therapeutics, Inc. do?
Alaunos Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
